Apellis Pharmaceuticals Inc (APLS) Price

Dr. Cedric Francois is the President of Apellis Pharmaceuticals Inc, joining the firm since 2009.

The current price of APLS is $23.11, it has decreased 1.11% in the last trading day.

Apellis Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care

Apellis Pharmaceuticals Inc's current market cap is $2.9B

According to wall street analysts, 21 analysts have made analyst ratings for Apellis Pharmaceuticals Inc, including 7 strong buy, 11 buy, 9 hold, 0 sell, and 7 strong sell

Looks like you're watching a classic biotech pullback, anon. Apellis (APLS) is down around 2.17% today, not because of some catastrophic news, but likely due to a technical correction after a recent run-up . The stock is cooling off as the market digests recent presentations and weighs the company's long road to profitability.

Here’s the breakdown of what’s actually happening with APLS, so you can stop staring at the 1-minute chart.

• Technical Cool-Down: The stock is experiencing a technical pullback. The daily RSI, which was nearing the overbought territory at almost 70 on September 4, has since dropped to the low 40s . This indicates that the recent buying momentum has faded. Furthermore, the daily MACD is showing a bearish crossover, confirming this short-term downward trend . The price is currently fighting to stay above its support level around $20.75 after failing to break the $26.23 resistance .

• No Major Negative Catalyst: There hasn't been a major negative press release today causing the drop. The most recent news includes a transcript from the Baird Global Healthcare Conference on September 9, where the company presented its strategy , and a Yahoo Finance article from today discussing the company's timeline to profitability—a standard concern for biotechs with irregular cash flow . This price action feels more like market digestion than a reaction to a specific event.

• Analyst Sentiment vs. Price Action: Here's where the alpha is. While the price is dipping, Wall Street analysts remain very bullish. The stock has a consensus "BUY" rating, with 18 out of 21 analysts recommending a "Buy" or "Strong Buy" . The mean price target is $38.53, suggesting a potential 55% upside from the current price . This disconnect between the short-term price action and strong analyst conviction could signal an opportunity.

• Key Levels to Watch:

  • Support: The immediate support level is at $20.75. A break below this could see the price fall towards the next major support at $16.10 .
  • Resistance: The key hurdle to overcome is $26.23. A solid break above that could signal a resumption of the uptrend, with the next target at $31.17 .

The current move is a textbook example of technicals temporarily outweighing fundamentals. Keep an eye on that $20.75 support level, bro. If it holds, the bulls might come back to play. If not, you might get a chance to buy it cheaper or watch your bags get heavier.